Current understanding of the metabolism and biological actions of HDL

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 8, Issue 2, 2005, Pages 147-152

  Von Eckardstein, Arnold ^a   Hersberger, Martin ^a   Rohrer, Lucia ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Adenosine triphosphate binding cassette transporters; Atherosclerosis; Endothelium; HDL; Lysosphingolipids; Reverse cholesterol transport; Scavenger receptor BI

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; ABC TRANSPORTER G1; ABC TRANSPORTER G4; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL ACYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN; LIVER X RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE SYNTHASE; PHOSPHOLIPID TRANSFER PROTEIN; PROSTACYCLIN; PROTEIN KINASE B; RETINOID X RECEPTOR; RETINOID X RECEPTOR GAMMA; SCAVENGER RECEPTOR BI; SPHINGOLIPID; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE; SPHINGOSYLPHOSPHORYLCHOLINE; SULFOGALACTOSYLSPHINGOSINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOCYTE; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CYTOKINE PRODUCTION; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENZYME PHOSPHORYLATION; HUMAN; LEUKOCYTE ADHERENCE; LIPID METABOLISM; LIPID OXIDATION; LIPID PEROXIDATION; NONHUMAN; PLEIOTROPY; PROTEIN EXPRESSION; REVIEW;

EID: 14244265399     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075197-200503000-00007     Document Type: Review

References (37)

1. Hersberger M, von Eckardstein A. Low high density lipoprotein cholesterol - physiological background, clinical importance and drug treatment. Drugs 2003; 63:1907-1945.
2. Connelly MA, Williams DL. Scavenger receptor BI: a scavenger receptor with a mission to transport high density lipoprotein lipids. Curr Opin Lipidol 2004; 15:287-295.
3. Wang N, Tall AR. Regulation and mechanisms of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003; 23:1178-1184.
4. Wang N, Lan D, Chen W, et al. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci U S A 2004; 101:9774-9779. The authors show that the transfection of cells with ABCG1 and ABCG4 increases HDL-induced cholesterol efflux. ABCG1 and ABCG4 are strongly expressed by macrophages, especially after stimulation with oxysterols. RNA interference reduced the expression of ABCG1 and ABCG4 in macrophages, and in parallel, cholesterol efflux to HDL.
5. Van Eck M, Bos IS, Hildebrand RB, et al. Dual role for scavenger receptor class B, type I on bone marrow-derived cells in atherosclerotic lesion development. Am J Pathol 2004; 165:785-794. By the use of bone marrow transplantation in SR-B1-deficient mice, the authors found a time-dependent pro or anti-atherogenic effect of SR-B1 expression in macrophages.
6. Chroni A, Liu T, Gorshkova I, et al. The central helices of ApoA-I can promote ATP-binding cassette transporter A1 (ABCA1)-mediated lipid efflux. Amino acid residues 220-231 of the wild-type ApoA-1 are required for lipid efflux in vitro and high density lipoprotein formation in vivo. J Biol Chem 2003; 278:6719-6730.
7. Singaraja RR, Brunham LR, Visscher H, et al. Efflux and atherosclerosis: the clinical and biochemical impact of variations in the ABCA1 gene. Arterioscler Thromb Vasc Biol 2003; 23:1322-1332.
8. Joyce C, Freeman L, Brewer HBr, Santamarina-Fojo S. Study of ABCA1 function in transgenic mice. Arterioscler Thromb Vasc Biol 2003; 23:965-971.
9. Tontonoz P, Mangelsdorf DJ. Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 2003; 17:985-993.
10. Navab M, Ananthramaiah GM, Reddy ST, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004; 45:993-1007.
11. ••] made the potentially important finding that myeloperoxidase-modified apolipoprotein A-I containing 3-chlorotyrosine or nitrotyrosine are enriched in atherosclerotic lesions and plasmas of patients with coronary heart disease. These modifications interfere with the ability of apolipoprotein A-I to induce cholesterol efflux. These findings may translate into a novel risk or disease marker for the identification of patients with atherosclerosis.
12. ••].
13. Getz GS, Reardon CA. Paraoxonase, a cardioprotective enzyme: continuing issues. Curr Opin Lipidol 2004; 15:261-267.
14. Mackness M, Durrington P, Mackness B. Paraoxonase 1 activity, concentration and genotype in cardiovascular disease. Curr Opin Lipidol 2004; 15:399-404.
15. Spieker LE, Sudano I, Hurlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemia.. Circulation 2002; 105:1399-1402.
16. Bisoendial PJ, Hovingh GK, Levels JH, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 2003; 107:2944-2948.
17. Calabresi L, Gomaraschi M, Franceschini G. Endothelial protection by high-density lipoproteins: from bench to bedside.. Arterioscler Thromb Vasc Biol 2003; 23:1724-1731.
18. Mineo C, Shaul PW. HDL Stimulation of endothelial nitric oxide synthase: a novel mechanism of HDL action. Trends Cardiovasc Med 2003; 13:226-231.
19. Ramet ME, Ramet M, Lu Q, et al. High-density lipoprotein increases the abundance of eNOS protein in human vascular endothelial cells by increasing its half-life. J Am Coll Cardiol 2003; 41:2288-2297.
20. Ozaki H, Hla T, Lee MJ. Sphingosine-1-phosphate signaling in endothelial activation. J Atheroscler Thromb 2003; 10:125-131.
21. Nofer JR, van der Giet M, Tolle M, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 2004; 113:569-581. Using in-vitro experiments and in-vivo studies in EDG3 [=S1P(3)]-deficient mice the authors identify HDL as a carrier of bioactive lysophospholipids (i.e. S1P, lysosulfatid and sphingosylphosphorylcholine), which regulate vascular tone via binding to EDG3, the activation of Akt and stimulation of intracellular calcium ion release and thus endothelial nitric oxide synthase phosphorylation. This mechanism may contribute to the vasoactive and, thus, the anti-atherogenic effects of HDL.
22. Assmann G, Nofer JR. Atheroprotective effects of high-density lipoproteins. Annu Rev Med 2003; 54:321-341.
23. Norata GD, Callegari E, Inoue H, Catapano AL. HDL3 induces cyclooxygenase-2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CRE-dependent pathway: effects on COX-2/PGI-synthase coupling. Arterioscler Thromb Vasc Biol 2004; 24:871-877. The authors provide evidence for a novel antiatherogenic effect of HDL on endothelial cells. They show that HDL modulates cyclooxygenase 2/prostaglandin I synthase activity via both p38 mitogen-activated protein kinase-dependent cyclooxygenase 2 messenger RNA stability and transcription and both caveolin-1-dependent prostaglandin I synthase shuttling and cyclooxygenase 2 coupling.
24. Wadham C, Albanese N, Roberts J, et al. High-density lipoproteins neutralize C-reactive protein proinflammatory activity. Circulation 2004; 109:2116-2122. In human umbilical vein endothelial cells, C-reactive protein upregulates the expression of adhesion molecules. This potentially atherogenic effect was completely prevented by HDL and an oxidized phospholipid component thereof (1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine).
25. Barter PJ, Baker PW, Rye KA. Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr Opin Lipidol 2002; 13:285-288.
26. Nofer JR, Geigenmüller S, Göpfert C, et al. High density lipoprotein-associated lysosphingolipids reduce E-selectin expression in human endothelial cells. Biochem Biophys Res Commun 2003; 310:98-103.
27. Thiemermann C, Patel NS, Kvale EO, et al. High density lipoprotein (HDL) reduces renal ischemia/reperfusion injury. J Am Soc Nephrol 2003; 14:1833-1843.
28. Calabresi L, Rossoni G, Gomaraschi M, et al. High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release. Circ Res 2003; 92:330-337.
29. Hyka N, Dayer JM, Modoux C, et al. Apolipoprotein A-I inhibits the production of interleukin-1 beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 2001; 97:2381-2390.
30. Robbesyn F, Garcia V, Auge N, et al. HDL counterbalance the proinflammatory effect of oxidized LDL by inhibiting intracellular reactive oxygen species rise, proteasome activation, and subsequent NF-κB activation in smooth muscle cells. Faseb J 2003; 17:743-745.
31. Nofer JR, Levkau B, Wolinska I, et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem 2001; 276:34480-34485.
32. Kimura T, Sato K, Malchinkhuu E, et al. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler Thromb Vasc Biol 2003; 23:1283-1288.
33. Roehrich ME, Mooser V, Lenain V, et al. Insulin-secreting beta-cell dysfunction induced by human lipoproteins. J Biol Chem 2003; 278:18368-18375.
34. Nofer JR, Fobker M, Hobbel G, et al. Activation of phosphatidylinositol- specific phospholipase C by HDL-associated lysosphingolipid. Involvement in mitogenesis but not in cholesterol efflux. Biochemistry 2000; 39:15199-15207.
35. Parhami F, Basseri B, Hwang J, et al. High-density lipoprotein regulates calcification of vascular cells. Circ Res 2002; 91:570-576.
36. Rohrer L, Hersberger M, von Eckardstein A. High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol 2004; 15:269-278.
37. von Eckardstein A. Therapeutic approaches to high density lipoproteins. Drug Discov Today Therap Strat 2004; 1:177-187.